$824.6 K

ATMS Mkt cap, 25-Jan-2021
Artemis Therapeutics Net income (Q2, 2020)-6 K
Artemis Therapeutics EBIT (Q2, 2020)-57 K
Artemis Therapeutics Cash, 30-Jun-20203 K

Artemis Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.7m1.1m1.3m244.0k

Cost of goods sold

893.0k517.0k564.0k40.0k

Gross profit

2.9m544.0k724.0k204.0k

Gross profit Margin, %

76%51%56%84%

Sales and marketing expense

1.2m432.0k205.0k43.0k

R&D expense

444.0k408.0k303.0k48.0k89.0k309.0k246.0k

General and administrative expense

1.5m666.0k567.0k463.0k164.0k166.0k730.0k526.0k168.0k

Operating expense total

3.1m1.5m1.1m(200.0k)164.0k255.0k1.0m772.0k168.0k

EBIT

(269.0k)(962.0k)(351.0k)404.0k(164.0k)255.0k(1.0m)(772.0k)(168.0k)

EBIT margin, %

(7%)(91%)(27%)166%

Interest expense

53.0k30.0k25.0k

Investment income

259.0k(6.0k)

Pre tax profit

(327.0k)(850.0k)(298.0k)

Income tax expense

9.0k(53.0k)

Net Income

(489.0k)(1.1m)(298.0k)362.0k(139.0k)264.0k(1.1m)(513.0k)(121.0k)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

948.0k1.0m209.0k190.0k516.0k367.0k315.0k300.0k244.0k

Cost of goods sold

223.0k226.0k112.0k124.0k160.0k180.0k112.0k83.0k82.0k

Gross profit

725.0k780.0k97.0k66.0k356.0k187.0k203.0k217.0k162.0k

Gross profit Margin, %

76%78%46%35%69%51%64%72%66%

Sales and marketing expense

220.0k245.0k179.0k137.0k71.0k51.0k53.0k48.0k43.0k

R&D expense

113.0k105.0k134.0k113.0k95.0k83.0k91.0k70.0k35.0k12.0k47.0k99.0k78.0k71.0k58.0k60.0k

General and administrative expense

347.0k348.0k208.0k140.0k157.0k125.0k130.0k131.0k122.0k95.0k34.0k78.0k30.0k40.0k23.0k18.0k138.0k142.0k149.0k229.0k154.0k143.0k20.0k70.0k22.0k19.0k57.0k

Operating expense total

680.0k698.0k521.0k390.0k323.0k259.0k274.0k249.0k(540.0k)107.0k34.0k78.0k30.0k40.0k23.0k18.0k185.0k241.0k227.0k300.0k212.0k203.0k20.0k70.0k22.0k19.0k57.0k

EBIT

45.0k82.0k(424.0k)(324.0k)33.0k(72.0k)(71.0k)(32.0k)702.0k(107.0k)(34.0k)(78.0k)(30.0k)(40.0k)(23.0k)(18.0k)(185.0k)(241.0k)(227.0k)(300.0k)(212.0k)(203.0k)(20.0k)(70.0k)(22.0k)(19.0k)(57.0k)

EBIT margin, %

5%8%(203%)(171%)6%(20%)(23%)(11%)288%

Investment income

(5.0k)89.0k71.0k95.0k(1.0k)1.0k(2.0k)(2.0k)(2.0k)

Pre tax profit

130.0k108.0k(470.0k)(310.0k)92.0k

Income tax expense

(53.0k)

Net Income

128.0k108.0k(470.0k)(420.0k)(59.0k)(111.0k)(92.0k)38.0k673.0k(127.0k)(33.0k)(72.0k)(18.0k)(40.0k)(18.0k)(18.0k)(185.0k)(246.0k)(227.0k)(211.0k)(141.0k)(108.0k)(21.0k)(69.0k)(24.0k)(21.0k)(6.0k)

Artemis Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.4m596.0k334.0k613.0k628.0k907.0k525.0k7.0k2.0k

Accounts Receivable

536.0k145.0k45.0k

Prepaid Expenses

16.0k48.0k

Inventories

407.0k322.0k229.0k

Current Assets

2.9m1.1m672.0k896.0k706.0k972.0k583.0k27.0k22.0k

PP&E

66.0k48.0k29.0k

Total Assets

3.0m1.2m703.0k896.0k706.0k972.0k583.0k27.0k22.0k

Accounts Payable

221.0k84.0k145.0k5.0k71.8m

Current Liabilities

1.0m312.0k237.0k66.0k50.0k58.0k53.0k324.0k157.0k

Non-Current Liabilities

428.0k

Total Liabilities

1.2m418.0k275.0k106.0k55.0k58.0k481.0k324.0k260.0k

Common Stock

411.0k432.0k432.0k432.0k432.0k52.0k52.0k52.0k

Additional Paid-in Capital

17.8m17.8m17.8m17.8m17.8m(1.7m)1.5m1.6m1.9m

Retained Earnings

(16.5m)(17.6m)(17.9m)(17.6m)(17.7m)(264.0k)(1.4m)(1.9m)(2.2m)

Total Equity

1.7m738.0k428.0k790.0k651.0k914.0k102.0k(297.0k)(238.0k)

Financial Leverage

1.7 x1.6 x1.6 x1.1 x1.1 x1.1 x5.7 x-0.1 x-0.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.0m1.1m966.0k454.0k759.0k339.0k314.0k271.0k1.2m748.0k769.0k706.0k655.0k577.0k595.0k1.0m759.0k555.0k345.0k339.0k148.0k38.0k22.0k7.0k3.0k2.0k3.0k

Accounts Receivable

256.0k757.0k36.0k67.0k325.0k303.0k112.0k123.0k59.0k59.0k

Prepaid Expenses

49.0k26.0k11.0k66.0k44.0k44.0k40.0k57.0k49.0k46.0k46.0k40.0k30.0k44.0k33.0k26.0k16.0k31.0k17.0k11.0k60.0k

Inventories

336.0k363.0k431.0k406.0k364.0k315.0k319.0k275.0k

Current Assets

2.9m3.0m2.0m1.5m1.5m1.0m839.0k741.0k1.5m1.1m843.0k780.0k725.0k664.0k644.0k1.0m805.0k595.0k375.0k383.0k181.0k64.0k38.0k38.0k20.0k13.0k63.0k

PP&E

58.0k63.0k64.0k60.0k54.0k43.0k37.0k33.0k25.0k3.0k

Total Assets

3.0m3.0m2.1m1.6m1.6m1.1m881.0k779.0k1.5m1.1m843.0k780.0k725.0k664.0k644.0k1.0m805.0k595.0k375.0k383.0k181.0k64.0k38.0k38.0k20.0k13.0k63.0k

Accounts Payable

148.0k199.0k71.0k52.0k62.0k139.0k86.0k37.0k139.0k4.0k4.0k

Current Liabilities

1.1m1.1m493.0k417.0k513.0k324.0k198.0k123.0k371.0k78.0k56.0k68.0k51.0k50.0k50.0k68.0k61.0k55.0k51.0k52.0k53.0k144.0k189.0k154.0k156.0k163.0k214.0k

Non-Current Liabilities

339.0k265.0k169.0k

Total Liabilities

1.3m1.3m747.0k650.0k704.0k452.0k347.0k207.0k433.0k140.0k87.0k95.0k58.0k53.0k51.0k68.0k61.0k51.0k391.0k318.0k313.0k189.0k254.0k256.0k268.0k320.0k

Common Stock

42.3m411.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k432.0k2.9m2.9m51.0k51.0k52.0k52.0k52.0k52.0k52.0k52.0k52.0k52.0k

Additional Paid-in Capital

17.3m17.3m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m17.8m(1.7m)(1.7m)1.2m1.2m1.6m1.6m1.6m1.9m1.9m1.9m1.9m1.9m

Retained Earnings

(16.2m)(16.1m)(17.0m)(17.4m)(17.5m)(17.7m)(17.8m)(17.8m)(17.2m)(17.4m)(17.6m)(17.7m)(17.7m)(17.7m)(17.8m)(36.0k)(449.0k)(685.0k)(912.0k)(1.6m)(1.8m)(1.9m)(2.1m)(2.2m)(2.2m)(2.2m)(2.2m)

Total Equity

1.7m1.8m1.3m908.0k854.0k626.0k534.0k572.0k1.1m973.0k756.0k685.0k667.0k611.0k593.0k979.0k744.0k540.0k324.0k(8.0k)(137.0k)(249.0k)(151.0k)(216.0k)(236.0k)(255.0k)(257.0k)

Financial Leverage

1.8 x1.7 x1.6 x1.7 x1.8 x1.7 x1.6 x1.4 x1.4 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x-47.9 x-1.3 x-0.3 x-0.3 x-0.2 x-0.1 x-0.1 x-0.2 x

Artemis Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(489.0k)(1.1m)(298.0k)362.0k(139.0k)(264.0k)(1.1m)(513.0k)(121.0k)

Depreciation and Amortization

23.0k25.0k19.0k4.0k

Accounts Receivable

(317.0k)391.0k100.0k45.0k

Inventories

(178.0k)85.0k93.0k229.0k

Accounts Payable

74.0k(137.0k)61.0k(140.0k)(5.0k)

Cash From Operating Activities

65.0k(1.3m)(246.0k)465.0k(190.0k)(276.0k)(926.0k)(518.0k)(108.0k)

Purchases of PP&E

(22.0k)(7.0k)

Cash From Investing Activities

(525.0k)501.0k(16.0k)(186.0k)205.0k

Cash From Financing Activities

(57.0k)544.0k103.0k

Net Change in Cash

(517.0k)(796.0k)(262.0k)279.0k15.0k(382.0k)(518.0k)(5.0k)

Artemis Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.8 x